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Abstract
Genetic variation at 8q24 is associated with prostate, bladder, breast, colorectal, thyroid, lung,
ovarian, UADT, liver and stomach cancers. However, a role for variation at 8q24 in familial
clustering of upper gastrointestinal cancers has not been studied. In order to explore potential
inherited susceptibility, we analyzed epidemiologic data from a population-based case-control
study of upper gastrointestinal cancers from Taixing, China. The study population includes 204
liver, 206 stomach, and 218 esophageal cancer cases and 415 controls. Associations between 8q24
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rs1447295, rs16901979, rs6983267 and these cancers were stratified by family history of cancer.
Odds ratios and 95% confidence intervals were adjusted for potential confounders: age, sex,
education, tobacco smoking, alcohol consumption, and BMI at interview. We also adjusted for
hepatitis B and aflatoxin (liver cancer) and Helicobacter pylori (stomach cancer). In a dominant
model, among those with a family history of cancer, rs1447295 was positively associated with
liver cancer (ORadj 2.80; 95% CI 1.15–6.80). Heterogeneity was observed (Pheterogeneity=0.029)
with rs6983267 and liver cancer, with positive association in the dominant model among those
with a family history of cancer and positive association in the recessive model among those
without a family history of cancer. When considered in a genetic risk score model, each additional
8q24 risk genotype increased the odds of liver cancer by two-fold among those with a family
history of cancer (ORadj 2.00; 95% CI 1.15–3.47). These findings suggest that inherited
susceptibility to liver cancer may exist in the Taixing population and that variation at 8q24 might
be a genetic component of that inherited susceptibility.
Keywords
Liver cancer; stomach cancer; esophageal cancer; hepatitis B; 8q24 SNPs; family history of cancer
Introduction
Family history of cancer has been associated with several cancers, including cancers of the
liver, stomach, and esophagus [1–7]. Shared environmental risk factors, such as hepatitis B
and C, and Helicobacter pylori (H. pylori) infection, have been associated with liver and
stomach cancers, respectively, and might have a role in familial clustering of these cancers.
Familial clustering of upper gastrointestinal (GI) cancers might also be attributable to
inherited genetic factors. Prospective cohort studies of twins have suggested that one-third
of most cancers are attributable to inherited genetic factors [8,9]. Genetic studies of familial
cancers often focus on highly penetrant genetic mutations; however, low penetrance genetic
factors have been associated with susceptibility to liver, stomach, and esophageal cancers
[10–13]. A few of the low penetrance genetic factors that are of great interest to cancer
epidemiology are at 8q24.
Genome-wide association studies (GWAS) and case-control studies have associated
variation at 8q24 with prostate, bladder, breast, colorectal, thyroid, lung, ovarian, UADT,
liver and stomach cancers [9,14–20,12,21–24]. Colorectal cancer cases with a family history
of cancer have been observed as having a greater number of 8q24 risk alleles, in comparison
to those colorectal cancer cases without a family history of colorectal cancer [25].
Additionally, in a family history-stratified analysis of cancer in a Polish population, 8q24
single nucleotide polymorphism (SNPs) were associated with prostate, laryngeal, lung, and
kidney cancers among those with a family history of cancer, with noteworthy heterogeneity
in family history-stratified associations for laryngeal and lung cancers [26]. In this study, we
stratified the association of three 8q24 SNPs (rs1447295, rs16901979, rs6983267) and liver,
stomach, and esophageal cancers in a Chinese population by family history of cancer. To
our knowledge, this is the first study of 8q24 SNPs, family history of cancer, and these three
upper GI cancers in a Chinese population.
Methods
Study Design and Participants
Epidemiologic data and biological specimens were collected in a population-based case-
control study in Taixing City, Jiangsu Province, China. Study protocols were approved by
the Institutional Review Board at the University of California, Los Angeles and all
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participants provided written informed consent. The study design and population have been
described in detail elsewhere [27,28,13]. Briefly, eligible cases and controls were residents
of Taixing City for at least 10 years and were at least 20 years of age at the time of
recruitment. Newly diagnosed cases of stomach, liver, and esophageal cancers were
identified between June 1, 2000 and December 30, 2000 using the Taixing Population-based
Tumor Registry from the Taixing Center for Disease Prevention and Control. Population-
based controls were randomly selected from a list of Taixing City residents and frequency-
matched to all upper GI cases on sex, age (5-year categories), and residential village or
block. The participation rates were 65% for stomach (n=206), 57% for liver (n=204), 67%
(n=218) for esophageal cancer cases, and 89% (n=415) for controls.
Epidemiologic Data and Biological Specimen Collection
Epidemiologic data were collected by a standard questionnaire during 40–60 minute
interviews with a trained interviewer. Questionnaires were standardized with questions on
common exposures, in addition to specific questions for each cancer site. The collected data
include demographics, personal habits, cigarette smoking, passive smoke exposure, alcohol
consumption, tea consumption, occupational history, family history of cancer in
consanguineal relatives and non-consanguineal spouses, frequency of diet and food intake,
and medical history. DNA was isolated from peripheral blood samples collected from 395
interviewed controls and from 196 stomach, 194 liver, and 205 esophageal cancer cases
interviewed. Measurement of exposure to hepatitis B and H. pylori has been described
previously [28,13]. Plasma aflatoxin B1 (AFB1)-albumin adduct levels were determined
using a competitive enzyme-linked immunosorbent assay, as described previously [29].
Biological specimens have been stored at −70°C in the Molecular Epidemiology
Laboratories of Fudan University School of Public Health and the University of California,
Los Angeles School of Public Health.
SNP Selection and Genotyping
Taixing study biospecimens were previously genotyped for three 8q24 SNPs (rs1447295,
rs16901979, rs6983267) and main associations reported [30]. Genotypic data for all three
8q24 SNPs are included in this study given the location of the SNPs in unique regions of
8q24, published associations in GWAS and case-control studies of colorectal and prostate
cancers, and linkage disequilibrium below the threshold of r2=0.80 [31,32,14,33,34,15,18].
SNP genotyping was performed on a TaqMan platform with an ABI 7900HT Sequence
Detection System (Applied Biosystems, Foster City, CA). SNP-specific primers and probes
were custom-designed for the ABI TaqMan system. Approximately 5% of samples were
randomly selected and duplicated for quality control. The concordance rate between
duplicates was >99%. The automatic call rates were >96% for all three SNPs. Laboratory
technicians were blinded to the case/control status of all samples and to the inclusion of
duplicate samples for quality control.
Statistical Analysis
All data analyses were performed using SASv9.2 software (SAS Institute Inc., Cary, NC,
USA). Linkage disequilibrium between 8q24 SNPs was examined using the Proc Allele
command in SAS for pairwise comparison of all three 8q24 SNP alleles in controls. Family
history of any cancer (yes or no) and family history of index cancer (yes or no) were
determined by self-reported history of cancer in at least one consanguineal relative (mother,
father, sister, brother, daughter, son, grandfather, grandmother, maternal/paternal uncle,
maternal/paternal aunt). Unconditional logistic regression was used to estimate crude and
adjusted odds ratios (ORadj) and their 95% confidence intervals (CI). Covariates adjusted for
include age (continuous), sex (male=0 or female=1), education (illiterate=0, primary
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school=1, middle school=2, senior high school/bachelor/higher degree=3), smoking status
(never=0 or ever=1), number of smoking pack-years (continuous), alcohol drinking
frequency (never=0, occasionally=1, often=2, everyday=3), body-mass-index (BMI [kg/m2],
continuous), AFB1-albumin adduct levels (liver only, quintiles), hepatitis B serum antigen
(liver only, positive=1 or negative=0), and H. pylori infection (stomach only, positive=1 or
negative=0). The Taixing study population is 100% Han Chinese, therefore, ethnicity was
not included as a covariate.
Tests for Hardy-Weinberg Equilibrium and differences in minor allele frequencies were
previously evaluated for all three SNPs using the x2 test [30]. We used the TT genotype as
the referent for rs6983267 and the CC genotype as the referent for rs1447295 and
rs16901979, so that odds ratios were modeled for the genotype homozygous for the cancer
risk alleles [35–37]. Odds ratios for the stratified analysis were estimated using
unconditional logistic regression, with adjustment for previously described covariates.
Cancer risk estimation can be improved by examining multiple loci simultaneously [38–40].
Therefore, in this study, we use a simple count approach to genetic risk scoring to examine
the three 8q24 SNPs collectively for potential improvement in the risk estimated with each
individual SNP. Under the simple count approach, we calculated a SNP-set score by
assigning a value of “0” to the major homozygous genotype of each SNP and “1” to the
heterozygous and minor homozygous genotype of each SNP (dominant model). In order to
reduce the bias caused by missing data, we did not include any participants who had one or
more missing genotypes for the 8q24 SNPs. Values were summed across all three SNPs in
order to determine a SNP-set score for each participant. The dominant model was chosen
based on our previously published analysis of the main association of each SNP with each
cancer site [30].
To test for departures from multiplicativity, we compared the full unconditional logistic
regression model with the product term (family history x SNP [dichotomized under the
dominant model]) to the full model without the product term. The antilog of the coefficient
estimated for the product term was interpreted as the ratio of odds ratios (ROR), with a
ROR≠1 indicating a departure from multiplicativity and from the null hypothesis. The RORs
and their 95% CIs were estimated using unconditional logistic regression, with adjustment
for previously described covariates.
Results
Select characteristics of the Taixing study population were previously reported and are
presented in Table 1 [27,28,13]. Briefly, liver, esophageal, and stomach cancer cases are
78%, 65%, and 67% male, and 69% of controls are male. Tobacco smoking (ever smoking)
was reported by 53%, 54%, and 53% of liver, esophageal, and stomach cancer cases, and by
48% of controls. Approximately 65% of liver cancer cases were positive for hepatitis B
exposure and 9% were positive for hepatitis C exposure, compared to 25% (hepatitis B) and
3% (hepatitis C) of controls. Thirty-five percent (35%) of stomach cancer cases were
exposed to H. pylori as defined by the presence of anti-(CagA-HP) IgG, compared to 28% of
controls. Among 202 esophageal cases, cancer was located in the upper (n=125, 61.8%),
middle (n=58, 28.7%), and lower (n=19, 9.4%) third of the esophagus. Cancer was located
in the cardia (n=93, 71%), body (n=18, 13.7%), antrum (n=17, 13%), and pylorus (n=3,
2.3%) of 131 stomach cancer cases. Liver cancer was distributed between the left (n=78,
55.3%) and right (n=63, 44.7%) lobes in 141 liver cancer cases.
Family history of any cancer was positively associated with liver (ORadj 2.52; 95% CI,
1.63–3.88) and stomach (ORadj 1.41; 95% CI 0.91–2.18) cancers (Table 2). The positive
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associations persisted in the analysis of family history of liver cancer (ORadj 3.76; 95% CI
2.13–6.63) and family history of stomach cancer (OR adj 4.56; 95% CI 2.17–9.58); however,
no clear association was found between family history of cancer and esophageal cancer
(Table 2). The 8q24 SNPs included in this study (rs6983267, rs1447295, rs16901979) are
not in linkage disequilibrium (r2<0.20) with one another. Genotype frequencies for their
association with liver, stomach, and esophageal cancers have been reported elsewhere [30]
and are presented in Table 3. In our previously published study, we did not observe a
relationship between the A risk allele of rs1447295 and esophageal, stomach, or liver
cancers [30]. In this study, after stratification on family history of cancer (Table 4), we
observed a positive association between rs1447295 and liver cancer among those with a
family history of cancer (ORadj 2.80; 95% CI 1.15–6.80), in the dominant model, consistent
with a departure from multiplicativity (RORadj 2.54; 95% CI 0.94–6.87). The observed
association persisted in the hepatitis B negative subgroup analysis (ORadj 3.52; 95% CI
1.10–11.1) presented in Table 5 and is consistent with the analysis of family history of
cancer in first-degree relatives only (Supplemental Table).
In this study, we observed family history of cancer as a modifier of the association of
rs6983267 and liver cancer (Pheterogeneity=0.029). Among those with family history of
cancer, the GT heterozygous genotype (ORadj 2.67; 95% CI 1.00–6.82) and rs6983267 in
the dominant model (ORadj 2.17; 95% CI 0.89–5.28) are positively associated with liver
cancer; however, among those without a family history of cancer, the positive association is
observed for the GG rare homozygous genotype (ORadj 2.05; 95% CI 0.96–4.38) and
rs6983267 in the recessive model (ORadj 2.15; 95% CI 1.11–4.16). A similar pattern of
association was also suggested among those with a family history of cancer in first-degree
relatives only (Supplemental Table). The observed heterogeneity is consistent with a
departure from multiplicativity (RORadj 1.81; 95% CI 0.67–4.85) and persisted in the
hepatitis B negative subgroup analysis (Pheterogeneity=0.040) presented in Table 5. No clear
association was observed between 8q24 SNPs and stomach and esophageal cancers in
family history-stratified analyses.
The departures from multiplicativity observed with the 8q24 SNPs are consistent with the
genetic risk score for the 8q24 SNP-set and family history of cancer (Table 6). There is a
two-fold greater risk of liver cancer (ORadj 2.00; 95% CI 1.15–3.47), per additional 8q24
SNP risk genotype, among those with a family history of cancer (Pheterogeneity=0.086).
Discussion
In this study, family history of cancer is associated with cancers of the liver and stomach.
We observed that rs1447295 was positively associated with liver cancer among those who
reported having a family history of cancer. The relationship between the A risk allele of
rs1447295and liver cancer in those with a family history of cancer, but not in those without
a family history of cancer, is consistent with previously published studies that reported
positive associations for rs1447295 and familial prostate cancer [41–44]. A functional role
for the A risk allele of rs1447295 has yet to be established. There is evidence of linkage
disequilibrium (LD) between rs1447295 and DG8S737, a microsatellite that is positively
associated with prostate cancers, and also the suggestion that both mark a functional causal
variant [45,18,42,43,19,46]. DG8S737 was not assayed in this study and we could not assess
a potential association with liver cancer or potential LD with rs1447295 within this
population.
In addition to our findings with rs1447295, we also observed heterogeneity in the family
history-stratified association of rs6983267 and liver cancer that might potentially indicate
inherited susceptibility to the risk associated with the recessive G allele in familial cancer
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clusters. Our findings in this candidate gene study of rs6983267 and liver cancer are similar
to another recent candidate gene study, where the G allele was associated with thyroid
cancer in a recessive inheritance model [23]. The Jones et al. (2012) study also observed
heterogeneity in the association of thyroid cancer and recessive GG homozygotes, in
comparison to GT heterozygotes. We did not detect an additive relationship for rs6983267
and liver cancer, among those with a family history of cancer, which might be due to sample
size or to a non-additive mechanism. Inherited allelic instability at rs6983267 might also
explain our findings of GT heterozygotes with a family history of cancer experiencing the
same risk as recessive GG homozygotes without a family history of cancer.
Functional studies have demonstrated that the G risk allele of rs6983267 enhances
transcription of the Myc oncogene, which in turn affects Wnt pathway signaling [47–55].
Beebe-Dimmer and colleagues have published their observations of preferential germline
transmission of the G risk allele of rs6983267 in familial prostate cancer cases [41].
Tuupanen and colleagues have suggested a role for allelic imbalance at rs6983267 and
amplification of the G risk allele by comparing germline rs6983267 genotypes of colorectal
cancer patients and their relatives, with somatic rs6983267 genotypes of patients’ tumors
[36,51]. In light of these studies, our findings are consistent with rs6983267 operating in
families as what Tuupanen et al. describe as a “germline predisposition SNP to somatic
tumor evolution” [36].
The heterogeneity in the 8q24 genetic risk score by family history of cancer is consistent
with previously reported observations in familial colorectal cancer cases [25] and could
potentially be explained by allelic transmission disequilibrium in families or by co-
inheritance of 8q24 loci with an unknown disease marker. Our findings demonstrate the
importance of including family history of cancer in studies of low penetrance genetic
variation to generate hypotheses that can be tested in subsequent family-based studies.
This study had some limitations. Although genotypic and infection-related data are not
affected by recall bias, recall bias may be present in self-reported family history of cancer
and may be differential. However, we expect this bias to be minimal given that previously
published studies have reported allelic transmission disequilibrium and have observed a
difference in the number of risk alleles transmitted to familial cancer cases [34,43,41,56]. A
strength of this study is the ability to stratify on family history of any cancer and family
history of index cancer in a racially homogenous population. Studies of familial clustering
of liver cancer in Asian populations have partially attributed observed positive associations
to hepatitis B infection. We cannot rule out shared environmental factors; however, we were
able to adjust our ORs for those infectious risk factors associated with liver and stomach
cancers, and shared within families. Our adjusted estimates are consistent with published
studies of hepatitis B-negative European and American populations, which reported ORs
ranging from 1.4–2.4 for the association of family history of cancer and liver cancer [2,5].
Furthermore, the magnitude and direction of associations that we observed in the overall
population persisted in our hepatitis B-negative subgroup analysis.
In conclusion, this study finds that the association of rs6983267 and rs1447295 with liver
cancer varies by family history of cancer. The hypothesis generated in this study, namely
that there is an inherited predisposition towards allelic imbalance or loss of heterozygosity at
rs6983267, warrants further investigation in larger population-based and family-based
studies. Further investigation is also needed into the genetic epidemiology of rs6983267 and
rs1447295, in order to understand the potential for linkage with causal markers or possible
transmission disequilibrium of risk alleles.
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Table 1
Select characteristics of cases and controls.
Liver Cancer Cases (%) Stomach Cancer Cases (%) Esophageal Cancer Cases (%) Controls (%)
Age in years (mean, SD) 53.9 13.0 61.5 9.8 60.6 9.6 57.7 11.8
Sex
 Female 45 (22.0) 68 (33.0) 77 (35.3) 128 (30.8)
 Male 159 (78.0) 138 (67.0) 141 (64.7) 287 (69.2)
BMI in kg/m2 (mean, SD) 21.6 2.5 21.5 2.7 21.9 2.8 22.3 2.5
Hepatitis B serum antigen
 Absent 72 (35.3) 312 (75.2)
 Present 132 (64.7) 102 (24.6)
 Missing 1 (0.2)
Helicobactor pylori
 Absent 130 (63.1) 251 (60.5)
 Present 71 (34.5) 114 (27.5)
 Missing 5 (2.4) 50 (12.0)
Education
 Illiterate 44 (21.6) 66 (32.0) 83 (38.1) 73 (17.6)
 Primary School 77 (37.8) 107 (51.9) 101 (46.3) 142 (34.2)
 Middle School 70 (34.3) 30 (14.6) 28 (12.8) 124 (29.9)
 Senior School 13 (6.4) 2 (1.0) 3 (1.4) 66 (15.9)
 Bachelor’s or higher 0 (0) 1 (0.5) 0 (0) 10 (2.4)
 Missing 3 (1.4)
Ever Smoking
 Never 85 (41.7) 92 (44.7) 94 (43.1) 217 (52.3)
 Ever 107 (52.5) 109 (52.9) 117 (53.7) 197 (47.5)
 Missing 12 (5.8) 5 (2.4) 7 (3.2) 1 (0.2)
Alcohol Drinking
 Never 87 (42.7) 111 (53.9) 116 (53.2) 207 (49.9)
 Occasionally 29 (14.2) 31 (15.1) 18 (8.3) 72 (17.3)
 Often 51 (25.0) 32 (15.5) 37 (17.0) 75 (18.1)
 Everyday 25 (12.3) 27 (13.1) 40 (18.3) 58 (14.0)
 Missing 12 (5.8) 5 (2.4) 7 (3.2) 3 (0.7)
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Table 2
Association between family history of cancer and upper gastrointestinal cancers.
Family History of Any Cancer Family History of Index Cancer
Cancer Ca/Co ORadj (95% CI) Ca/Co ORadj (95% CI)
Livera,b
 Without Family History 101/289 1.00 151/376 1.00
 With Family History 93/112 2.52 (1.63–3.88) 53/39 3.76 (2.13–6.63)d
 Unrelateds and Other Relatives 2/10
 Missing 8/4
 Total 204/415
Stomacha,c
 Without Family History 127/289 1.00 169/393 1.00
 With Family History 63/112 1.41 (0.91–2.18) 37/22 4.56 (2.17–9.58)
 Unrelateds and Other Relatives 13/10
 Missing 3/4
 Total 206/415
Esophagusa
 Without Family History 151/289 1.00 187/361 1.00
 With Family History 55/112 0.93 (0.61–1.44) 31/54 1.31 (0.74–2.32)
 Unrelateds and Other Relatives 5/10
 Missing 7/4
 Total 218/415
a
Adjusted for age, sex, education, smoking status, pack years, alcohol drinking frequency, and BMI.
b
Adjusted for hepatitis B antigen and aflatoxin exposure.
c
Adjusted for Helicobactor pylori infection.
d
Previously reported by Mu LN, Cao W, Zhang ZF et al. 2007. Cancer Causes and Controls.
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